Nat Commun:中南大学团队发布对新冠患者疾病进展的早期预测方式

2020-10-04 haibei MedSci原创

来自中南大学的研究人员在Nature Communicarions杂志发文,回顾性地研究了多家医院收治的中度COVID-19肺炎患者。

由重症急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的2019年冠状病毒病(COVID-19)疫情已迅速蔓延至全世界。大多数COVID-19患者的临床病程较轻,而一部分患者则表现为症状发作后迅速恶化(尤其是在7-14天内),成为伴有或不伴有急性呼吸窘迫综合征(ARDS)的严重疾病。目前没有针对重症患者的特异性抗冠状病毒治疗,雷米地西韦对重症COVID-19是否有显著的临床疗效仍需进一步确认。

已有的数据显示,重症COVID-19患者生存状况较差,往往需要密集利用医疗资源,其病例死亡率约为非重症患者的20倍。因此,对具有COVID-19严重并发症风险的患者的早期识别有着重要的临床意义。

多项研究报道,在入院患者中,严重COVID-19的发病率在15.7~26.1%之间,这些病例往往与异常的胸部计算机断层扫描(CT)结果和临床实验室数据有关。已有的研究指出,严重的COVID-19患者在CT上更容易出现毛玻璃状(GGO)、局部或双侧斑片状阴影和间质异常。这很可能反映了疾病的临床进展,也为研究胸部CT作为预测工具,对患者进行风险分层的临床效用提供了机会。

此外,胸部CT对COVID-19患者预后的预测价值也是值得肯定的,有助于有效治疗和控制疾病的扩散。

以往的研究表明,较高的肺部CT评分与中东呼吸综合征(MERS)患者的不良预后相关。胸部CT已被提出作为一种辅助方法,用于筛查流行期间疑似COVID-19肺炎的个体,并根据动态放射学变化监测治疗反应。

最近,来自中南大学的研究人员在Nature Communicarions杂志发文,回顾性地研究了多家医院收治的中度COVID-19肺炎患者,并观察至少14天,探讨其进展为重度COVID-19肺炎的早期CT和临床危险因素,并根据独立因素构建了图表。

同时,研究人员还比较了不同接触史或从症状发生到入院期间的患者的临床和CT特征,以深入了解CT结果、流行病学特征和炎症之间的关系。

该研究结果显示,CT严重度评分与炎症水平相关,年龄较大、较高的中性粒细胞与淋巴细胞比值(NLR)和入院时的CT严重度评分是短期进展的独立风险因素。基于这些危险因素的诺莫图(nomogram)在推导和验证队列中显示出良好的校准和辨别能力。

这些发现对预测COVID-19肺炎患者入院时的进展风险有一定的意义。CT检查可能有助于风险分层,指导入院时机。

 

原始出处:

Zhichao Feng et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nature Communications (2020). 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1907736, encodeId=4fe5190e7366b, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Aug 10 18:21:43 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087792, encodeId=4e97208e79291, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Apr 09 22:21:43 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906534, encodeId=67ba190653430, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed Sep 01 12:21:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884698, encodeId=09b31884698b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 07 13:21:43 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028614, encodeId=754110286140f, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Oct 04 13:21:43 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1907736, encodeId=4fe5190e7366b, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Aug 10 18:21:43 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087792, encodeId=4e97208e79291, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Apr 09 22:21:43 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906534, encodeId=67ba190653430, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed Sep 01 12:21:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884698, encodeId=09b31884698b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 07 13:21:43 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028614, encodeId=754110286140f, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Oct 04 13:21:43 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2021-04-09 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1907736, encodeId=4fe5190e7366b, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Aug 10 18:21:43 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087792, encodeId=4e97208e79291, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Apr 09 22:21:43 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906534, encodeId=67ba190653430, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed Sep 01 12:21:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884698, encodeId=09b31884698b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 07 13:21:43 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028614, encodeId=754110286140f, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Oct 04 13:21:43 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1907736, encodeId=4fe5190e7366b, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Aug 10 18:21:43 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087792, encodeId=4e97208e79291, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Apr 09 22:21:43 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906534, encodeId=67ba190653430, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed Sep 01 12:21:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884698, encodeId=09b31884698b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 07 13:21:43 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028614, encodeId=754110286140f, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Oct 04 13:21:43 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2021-02-07 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1907736, encodeId=4fe5190e7366b, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Aug 10 18:21:43 CST 2021, time=2021-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087792, encodeId=4e97208e79291, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Apr 09 22:21:43 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906534, encodeId=67ba190653430, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Wed Sep 01 12:21:43 CST 2021, time=2021-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884698, encodeId=09b31884698b4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Feb 07 13:21:43 CST 2021, time=2021-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028614, encodeId=754110286140f, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Sun Oct 04 13:21:43 CST 2020, time=2020-10-04, status=1, ipAttribution=)]
    2020-10-04 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

NATURE:Ad26疫苗:只打一针就可防新冠 

如今,新型冠状病毒的全球大流行迫使我们开发一种安全有效的疫苗,以结束这场疫情。对于全球部署和大流行控制,只需要一次免疫的疫苗将会带来最佳的效果。

CELL:对儿童新冠患者的多系统炎症综合征的免疫学研究 

研究人员在CELL杂志发文,其对健康儿童、COVID-19之前入组的川崎病儿童、SARS-CoV-2感染儿童和出现MIS-C的儿童的血液免疫细胞、细胞因子和自身抗体进行系统性分析。

CELL:重度COVID-19患者展现出髓细胞紊乱的特点

在一项双中心、双队列研究中,研究人员结合全血和外周血单核细胞的单细胞RNA测序和单细胞蛋白质组学,确定了轻度与重度COVID-19(来自109人的242个样本)的免疫细胞组成和活化随时间的变化。

CELL:先天性免疫标志物区分新冠高危患者

已有的研究显示,SARS-CoV-2引起的冠状病毒病(COVID-19)患者存在血液髓细胞的失调。但是,目前我们尚不清楚先天性髓细胞反应是否随疾病严重程度而出现不同.

NAT BME:通过一锅恒温方法对临床样品中的SARS-CoV-2 RNA进行灵敏的荧光检测

冠状病毒在世界各地频繁出现和迅速传播,为了快速诊断传染病,基于核酸的诊断因其快速和特异性而成为传统的基于培养或免疫分析的方法的替代品。